Browse Studies — Arctuva

Phase 1

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.

Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-Essential Thrombocytosis Myelofibrosis

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06327100

Phase 1

Phase I Study Accessing the Safety of Pacritinib in Combination With Talazoparib in Patients With Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 (Janus Kinase 2) Inhibition

This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with s…

Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more

Estimated

~$10 – $6,250

Fox Chase Cancer CenterNCT06218628

Molecular Biology of Polycythemia and Thrombocytosis

Our study is designed to characterize the clinical picture and genetic pattern of Polycythemia and Thrombocytosis. The purpose of this project is to find a gen…

PolycythemiaThrombocytosis

Estimated

~$10 – $750

University of UtahNCT00722527

Phase 2

Ropeginterferon Alfa-2b for MDS/MPN Overlap Syndromes, Including CMML and MDS/MPN-RS-T

This phase II trial tests the safety, best dose, and effectiveness of ropeginterferon alfa-2b for the treatment of patients with myelodysplastic syndrome/myelo…

Atypical Chronic Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm+2 more

Estimated

~$10 – $6,250

Jonsson Comprehensive Cancer CenterNCT07468916